Antibiotics Update: 3 Discovery Projects to Tackle MDR Gram-Negative Pathogens
Tim Opperman, Senior Research Scientist from Microbiotix, unveils new updates at SMi's next Annual Superbugs and Superdrugs USA Summit.
Iselin, NJ, July 13, 2017 --(PR.com)-- Supported by BARDA, CARB-X and big pharma, Superbugs & Superdrugs USA will provide insight into both traditional and non-traditional approaches towards combatting AMR whilst looking at financing initiatives and keeping attendees at the forefront of clinical breakthroughs.
Understanding the translational link between animals and humans; navigating the pitfalls of early drug discovery; and evaluating the potential of immunotherapies will be a major focus, as will hearing from a selection of biotech and pharma companies currently undertaking clinical research. This will include case studies from Pfizer, MedImmune, Merck, Visterra and ContraFect.
Event highlights will include a keynote presentation by Tim Opperman, Senior Research Scientist from Microbiotix.
The talk will discuss advances in the three-prong approach taken by Microbiotix to address the problem of MDR Gram-negative pathogens. It is claimed that all three discovery projects have demonstrated efficacy in murine models of infection.
Project 1 Virulance -Funded by CARB-X: Attendees will hear how a novel phenoxyacetamide series exhibits potent activity against type 3 secretion in Pseudomonas aeruginosa by targeting the assembled needle protein PscF.
Project 2 Intrinsic Resistance: Microbiotix will explain how novel pyranopyridine inhibitors of RND-type efflux pump inhibitors exhibit broad spectrum activity against pathogens of the Enterobacteriaceae and favourable pharmacokinetics in mice.
Project 3 Novel Essential Target: The talk will explore how a series of novel oxadiazoles bind to a unique site on the ribosome, resulting in potent inhibition of the essential non-stop ribosome rescue pathway in Gram-positive and negative pathogens, including MDR Neisseria gonorrhoeae and Francisella tularensis. These compounds exhibited potent antibacterial activity and oral bioavailability.
A full speaker line-up and detailed agenda is available at www.superbugs-usa.com
Superbugs & Superdrug’s USA will take place on 13th and 14th November at the Renaissance Woodbridge Hotel in Iselin, New Jersey.
Contact Information:
For media enquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email: tarri@smi-online.co.uk
For all other enquires contact the team on Tel: +44 (0)20 7827 6000 or email events@smi-online.co.uk
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at www.smi-online.co.uk
Understanding the translational link between animals and humans; navigating the pitfalls of early drug discovery; and evaluating the potential of immunotherapies will be a major focus, as will hearing from a selection of biotech and pharma companies currently undertaking clinical research. This will include case studies from Pfizer, MedImmune, Merck, Visterra and ContraFect.
Event highlights will include a keynote presentation by Tim Opperman, Senior Research Scientist from Microbiotix.
The talk will discuss advances in the three-prong approach taken by Microbiotix to address the problem of MDR Gram-negative pathogens. It is claimed that all three discovery projects have demonstrated efficacy in murine models of infection.
Project 1 Virulance -Funded by CARB-X: Attendees will hear how a novel phenoxyacetamide series exhibits potent activity against type 3 secretion in Pseudomonas aeruginosa by targeting the assembled needle protein PscF.
Project 2 Intrinsic Resistance: Microbiotix will explain how novel pyranopyridine inhibitors of RND-type efflux pump inhibitors exhibit broad spectrum activity against pathogens of the Enterobacteriaceae and favourable pharmacokinetics in mice.
Project 3 Novel Essential Target: The talk will explore how a series of novel oxadiazoles bind to a unique site on the ribosome, resulting in potent inhibition of the essential non-stop ribosome rescue pathway in Gram-positive and negative pathogens, including MDR Neisseria gonorrhoeae and Francisella tularensis. These compounds exhibited potent antibacterial activity and oral bioavailability.
A full speaker line-up and detailed agenda is available at www.superbugs-usa.com
Superbugs & Superdrug’s USA will take place on 13th and 14th November at the Renaissance Woodbridge Hotel in Iselin, New Jersey.
Contact Information:
For media enquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email: tarri@smi-online.co.uk
For all other enquires contact the team on Tel: +44 (0)20 7827 6000 or email events@smi-online.co.uk
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at www.smi-online.co.uk
Contact
SMi Group
Teri Arri
+44 (0) 207 827 6000
http://www.superbugs-usa.com/prcom
Teri Arri
+44 (0) 207 827 6000
http://www.superbugs-usa.com/prcom
Contact
Categories